November 9, 2017 10:03 AM EST
News Briefing

Mary Szela re­signs as CEO of Nov­e­l­ion; Chi­na is prov­ing to be a re­ward­ing mar­ket for As­traZeneca

Amber Tong

→ Af­ter re­or­ga­niz­ing Aege­ri­on and lead­ing the com­pa­ny through the merg­er with QLT that turned it in­to Nov­e­l­ion, CEO Mary Szela is leav­ing her po­si­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

As­traZeneca’s Truqap edges clos­er to prostate can­cer la­bel ex­pan­sion with Phase 3 win

A service from the Financial Times